Skip to main content
B

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 718 across all filing types
Latest filing 2026-04-14 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司关于安永华明会计师事务所（特殊普通合伙）履职情况的评估报告
Audit Report / Information Classification · 1% confidence The document is titled “关于安永华明会计师事务所（特殊普通合伙）履职情况的评估报告” (“Evaluation Report on the Performance of EY Hua Ming as Auditor”) and is a standalone report assessing the auditor’s qualifications, risk capacity, quality controls, and execution under Chinese regulatory rules. It is not an annual or interim financial report, nor a simple announcement or slide deck. It is specifically audit‐related information, separate from the auditor’s formal opinion on the financial statements. Under our taxonomy, standalone audit‐related disclosures fall under Audit Report / Information (AR).
2026-04-14 Chinese
百济神州有限公司2025年度内部控制评价报告
Audit Report / Information Classification · 1% confidence The document is a standalone “Internal Control Evaluation Report” (内部控制评价报告) prepared by the company’s board and management, detailing the year‐end internal control assessment under regulatory standards. It is not an annual or quarterly financial statement, nor an announcement of a meeting, dividend, financing, or regulatory notice; rather, it is a formal audit‐type report on the effectiveness of internal controls. This aligns with the “Audit Report / Information (AR)” category, which covers standalone audit or internal control evaluation reports.
2026-04-14 Chinese
百济神州有限公司董事会决议公告
Regulatory Filings Classification · 1% confidence The document is a board resolution announcement (董事会决议公告) detailing various items approved by the board (audited financial statements, annual report, special reports, profit distribution, etc.) and refers investors to the Shanghai Stock Exchange website for the full reports. It is not announcing management or board changes, nor is it the full report itself; rather, it is a regulatory filing announcing board decisions and linking to other disclosures. It does not fit the specific categories (MANG, 10-K, IR, ER, RPA, etc.), so it falls into the general regulatory filings fallback category.
2026-04-14 Chinese
百济神州有限公司2025年度内部控制审计报告
Audit Report / Information Classification · 1% confidence The document is a standalone internal control audit report issued by Ernst & Young (EY) for BeiGene Co., Ltd. covering the effectiveness of internal controls as of December 31, 2025. It includes auditor responsibilities, management responsibilities, and an audit opinion, which clearly identifies it as an Audit Report. Thus, it falls under the category “Audit Report / Information (AR).”
2026-04-14 Chinese
百济神州有限公司2026年度“提质增效重回报”行动方案
Management Reports Classification · 1% confidence The document is a substantive 10,000+ character standalone “Action Plan” issued by the company outlining 2025 performance summaries and the management’s strategic priorities, operational measures, and business outlook for 2026. It is not a short announcement, nor a formal Annual Report, earnings release, or proxy statement. Rather it presents detailed management discussion and analysis of past results, business trends, governance, investor relations, and forward-looking actions. This aligns with the “Management Reports (MDA)” category (management’s detailed explanation of financial results, business trends, and outlook).
2026-04-14 Chinese
百济神州有限公司董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 1% confidence The document is a detailed annual “履职情况报告” by the Board’s Audit Committee describing its audit oversight responsibilities, meetings, reviews of external and internal auditors, and evaluation of internal controls for the fiscal year 2025. It is not a full Annual Report (10-K), interim report (IR), or investor presentation, but a standalone audit-related report on committee activities. This aligns with the Audit Report / Information category.
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.